Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method
Laffel L, Sherr J, Liu J, Wolf W, Bispham J, Chapman K, Finan D, Titievsky L, Liu T, Hagan K, Gaglia J, Chandarana K, Pettus J, Bergenstal R. Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method. Diabetes Care 2024, 48: 273-278. PMID: 39699995, PMCID: PMC11770157, DOI: 10.2337/dc24-1474.Peer-Reviewed Original ResearchInternational Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies – Insulin Delivery
Biester T, Berget C, Boughton C, Cudizio L, Ekhlaspour L, Hilliard M, Reddy L, Um S, Schoelwer M, Sherr J, Dovc K. International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies – Insulin Delivery. Hormone Research In Paediatrics 2024, 97: 636-662. PMID: 39657603, PMCID: PMC11854989, DOI: 10.1159/000543034.Peer-Reviewed Original ResearchThe use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)
Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken R, Buckingham B, Danne T, Davis E, Dovč K, Forlenza G, Gillard P, Hofer S, Hovorka R, Jacobs P, Mader J, Mathieu C, Nørgaard K, Oliver N, O’Neal D, Pemberton J, Rabasa-Lhoret R, Sherr J, Sourij H, Tauschmann M, Yardley J, Riddell M. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia 2024, 68: 255-280. PMID: 39653802, PMCID: PMC11732933, DOI: 10.1007/s00125-024-06308-z.Peer-Reviewed Original ResearchConceptsEuropean Association for the Study of DiabetesPhysical activityInternational Society for Pediatric and Adolescent DiabetesType 1 diabetesRegular physical activityPosition statementDiabetes careStudy of DiabetesClinical practice pointsResponse to PAManaged PAsEuropean Association for the StudyHealth benefitsAge groupsExerciseAdolescent DiabetesAutomated insulin deliveryDiabetesInsulin deliveryGlucose target rangeTherapy optionsClinical trialsDeliveryGlucose levelsCareThe Use of Automated Insulin Delivery around Physical Activity and Exercise in Type 1 Diabetes: A Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD)
Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken R, Buckingham B, Danne T, Davis E, Dovc K, Forlenza G, Gillard P, Hofer S, Hovorka R, Jacobs P, Mader J, Mathieu C, Nørgaard K, Oliver N, O’Neal D, Pemberton J, Rabasa-Lhoret R, Sherr J, Sourij H, Tauschmann M, Yardley J, Riddell M. The Use of Automated Insulin Delivery around Physical Activity and Exercise in Type 1 Diabetes: A Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Hormone Research In Paediatrics 2024, 1-28. PMID: 39657609, DOI: 10.1159/000542287.Peer-Reviewed Original ResearchEuropean Association for the Study of DiabetesPhysical activityInternational Society for Pediatric and Adolescent DiabetesType 1 diabetesRegular physical activityPosition statementDiabetes careStudy of DiabetesClinical practice pointsResponse to PAManaged PAsEuropean Association for the StudyHealth benefitsAge groupsExerciseAdolescent DiabetesAutomated insulin deliveryDiabetesInsulin deliveryGlucose target rangeTherapy optionsClinical trialsDeliveryGlucose levelsGlucose fluctuationsConsensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
Shah V, Peters A, Umpierrez G, Sherr J, Akturk H, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs P, Lal R, Mader J, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho C, Ayers A, Tian T, Aaron R, Klonoff D. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. Journal Of Diabetes Science And Technology 2024, 19: 191-216. PMID: 39517127, PMCID: PMC11571606, DOI: 10.1177/19322968241291512.Peer-Reviewed Original ResearchGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsGLP-1RA therapyGLP-1RAGLP-1RAsType 1 diabetesReceptor agonistsAdjunctive therapyAbsence of randomized controlled trialsIncreasing prevalence of obesityUS Food and Drug AdministrationRisk of severe hypoglycemiaEffective adjunctive therapyPrevalence of obesityTreatment of T1DFood and Drug AdministrationRandomized controlled trialsDiabetic ketoacidosisAdjunctive treatmentMetabolic outcomesSevere hypoglycemiaAutomated insulin deliveryConsensus reportDrug AdministrationTherapyPsychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes
MacLeish S, Hood K, Polonsky W, Wood J, Bode B, Forlenza G, Laffel L, Buckingham B, Criego A, Schoelwer M, DeSalvo D, Sherr J, Hansen D, Conroy L, Huyett L, Vienneau T, Ly T, Group F. Psychosocial outcomes with the Omnipod® 5 Automated Insulin Delivery System in caregivers of very young children with type 1 diabetes. Diabetes Obesity And Metabolism 2024, 26: 5569-5579. PMID: 39300963, PMCID: PMC11949198, DOI: 10.1111/dom.15906.Peer-Reviewed Original ResearchPsychosocial outcomesSleep qualityEvaluate psychosocial outcomesPittsburgh Sleep Quality Index total scoreWell-beingType 1 diabetesSatisfaction survey scoresYoung childrenBurden caregiversAid useOverall sleep qualityAutomated insulin deliverySystem usabilityCaregiversSurvey scoresDiabetes managementPerceived system usabilityGlycaemic outcomesTotal scoreSleep durationDelivery satisfactionGlycaemic metricsSubscalesOutcomesUnique challengesGlycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System
DeSalvo D, Bode B, Forlenza G, Laffel L, Buckingham B, Criego A, Schoelwer M, MacLeish S, Sherr J, Hansen D, Ly T. Glycemic Outcomes Persist for up to 2 Years in Very Young Children with the Omnipod® 5 Automated Insulin Delivery System. Diabetes Technology & Therapeutics 2024, 26: 383-393. PMID: 38277156, DOI: 10.1089/dia.2023.0506.Peer-Reviewed Original ResearchType 1 diabetesExtension phaseEpisodes of diabetic ketoacidosisEpisodes of severe hypoglycemiaLong-term safetyLong-term useStandard therapyDiabetic ketoacidosisAutomated insulin deliverySevere hypoglycemiaYoung childrenConclusion:</i></b>Continuous glucose monitoring metricsExtension studyMethods:</i></b>MonthsGlycemic outcomesTarget rangeTrialsOmnipodHbA1cInsulin deliveryDelivery systemInsulin delivery systemsEpisodesSevere Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey
Sherr J, Laffel L, Liu J, Wolf W, Bispham J, Chapman K, Finan D, Titievsky L, Liu T, Hagan K, Gaglia J, Chandarana K, Bergenstal R, Pettus J. Severe Hypoglycemia and Impaired Awareness of Hypoglycemia Persist in People With Type 1 Diabetes Despite Use of Diabetes Technology: Results From a Cross-sectional Survey. Diabetes Care 2024, 47: 941-947. PMID: 38295397, DOI: 10.2337/dc23-1765.Peer-Reviewed Original ResearchImpaired awareness of hypoglycemiaSevere hypoglycemic eventsType 1 diabetesGlycemic targetsContinuous glucose monitoringInsulin delivery modalityDiabetes technologyImproved treatment strategiesAwareness of hypoglycemiaImpaired awarenessU.S. RESEARCH DESIGNAdvanced diabetes technologiesProportion of participantsCross-sectional surveySubgroup analysisSevere hypoglycemiaTreatment strategiesAutomated insulin deliveryImpact of continuous glucose monitoringGlycemic metricsHypoglycemic eventsObservational studyProportion of peopleResearch designInsulin delivery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply